Findings from School of Pharmacy Provides New Data on Nanoparticles (Galactosyl Bodipy-based Nanoparticles As a Type-i Photosensitizer for Hepg2 Cell Targeted Photodynamic Therapy).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      CHINA; ASIA
    • Abstract:
      A study conducted in Weifang, People's Republic of China, has developed galactosyl diiodo-BODIPY-based nanoparticles as a type-I photosensitizer for targeted photodynamic therapy of HepG2 cells. The nanoparticles were found to have high water solubility and excellent chemo- and photo-stability. The galactosyl-modified nanoparticles were able to target and concentrate on HepG2 cells, triggering cell death under specific light irradiation. This research provides a promising strategy for the construction of glycoside-recognized type-I photosensitizers for tumor cell imaging and photodynamic therapy. [Extracted from the article]
    • Abstract:
      Copyright of Medical Devices & Surgical Technology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)